- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
SpyGlass Pharma, Inc.(SGP)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Advisory Performance History (Simulated)
Upturn Advisory & Investor View for SGP
11/13/2026: SGP (2-star) has a low Upturn Star Rating. Not recommended to BUY.
SpyGlass Pharma, Inc. is a late-stage biopharmaceutical company focused on transforming glaucoma care through its proprietary drug-eluting intraocular lens technology. The company's primary strength lies in its innovative, procedure-integrated platform that addresses long-standing patient compliance issues with topical eye drops. While its recent IPO and strategic acquisition of manufacturing capabilities have established a solid foundation, the firm remains in a pre-revenue R&D phase. Key risks include the inherent uncertainty of Phase 3 clinical trials, regulatory approval hurdles, and strong competition from large, well-capitalized medical device incumbents. The stock is best suited for growth-oriented investors capable of managing the high volatility associated with clinical-stage biotechnology developments.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | The company offers high growth potential tied to the successful development and regulatory approval of its disruptive drug-delivery platform. |
| Momentum investor | Mixed fit | Momentum depends on clinical trial updates and news cycles; a strong fit while the news flow remains positive and the stock shows relative strength. |
| Value investor | Weak fit | As a pre-revenue biotech firm, the company lacks traditional valuation metrics like earnings or consistent cash flow. |
| Dividend investor | Weak fit | The company does not pay dividends and will likely require years of capital reinvestment before any income potential arises. |
| Low-risk investor | Weak fit | Clinical-stage biotechnology is inherently high-risk, characterized by volatility related to binary regulatory and clinical trial outcomes. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Clinical-stage biotech stocks often experience sharp price movements based on trial results and regulatory announcements. |
| Valuation risk | High | Valuations are based on future potential, leaving little room for error if clinical milestones are missed. |
| Competition risk (Ophthalmic device leaders) | Medium / high | Large incumbents have established distribution networks and physician relationships that could challenge market adoption. |
| Business quality | Medium | While the technology is innovative, the company is still in the process of building its manufacturing and commercial infrastructure. |
| Dividend income | Low / none | The company focuses entirely on R&D and capital preservation, offering no income to investors. |
| Execution risk | Medium / high | Success requires complex, multi-year Phase 3 clinical trials and successful FDA regulatory filings. |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.10B USD | Price to earnings Ratio - | 1Y Target Price 46.33 |
Price to earnings Ratio - | 1Y Target Price 46.33 | ||
Volume (30-day avg) 99.8K shares | Beta - | 52 Weeks Range 17.06 - 39.92 | Updated Date 11/14/2026 |
52 Weeks Range 17.06 - 39.92 | Updated Date 11/14/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.51 |
Sector & Industry Intelligence
Sector
Healthcare
Bullish- Sentiment
- Strong Bullish
- Momentum
- Momentum Steady
- BUY participation
- 62.6%
- Active BUY / eligible
- 72 / 115
- 30-Day BUY Count Change
- +35
- Market state
- Strong Bullish
The number of qualifying BUY stocks has remained relatively stable.
Industry
Biotechnology
- BUY participation
- 45.5%
- Active BUY / eligible
- 20 / 44
- 30-Day BUY Count Change
- +13
Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.
Price Behavior

Strong Uptrend
The stock has maintained a strong upward price trend across the last three quarters.

Choppy
The stock has experienced frequent reversals and pronounced short-term price swings.
Analysis of Past Performance
Type Stock | Historic Profit 14.42% | Avg. Invested days 27 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Advisory Rating ![]() | Upturn Advisory Performance | Stock Returns Performance |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals 
Financial Health Rating 
Growth Momentum Score 
Ownership 
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue) 
Economic Dimensions
Quantitative Style Profile 
Style Classification
Quality Focused
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Ophthalmic Drug Delivery Systems | The development and future commercialization of the BIM-IOL and BIM-DRS systems. | The company is currently an R&D-stage firm; revenue potential depends on successfully bringing its drug-eluting lens to market. |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 875.69M | Price to Sales(TTM) - |
Enterprise Value 875.69M | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding 33.45M | Shares Floating 6.51M |
Shares Outstanding 33.45M | Shares Floating 6.51M | ||
Percent Insiders 4.36 | Percent Institutions 96.32 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.

